Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation and Ductal Hyperplasia in Non-Human Primates

(2015) Teresa Vanessa Fiorentino et al.   AMERICAN JOURNAL OF PATHOLOGY

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

(2015) Reimar Wernich Thomsen et al.   DIABETES CARE

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2015) Silvio E. Inzucchi et al.   DIABETOLOGIA

Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization

(2015) Liam M. McCormick et al.   JACC-Cardiovascular Interventions

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors

(2015) Marcel H A Muskiet et al.   Lancet Diabetes & Endocrinology

Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database

(2015) Sunghwan Suh et al.   Diabetes & Metabolism Journal

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

(2014) Manfredi Rizzo et al.   Cardiovascular Diabetology

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

(2014) Rury R Holman et al.   LANCET

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis

(2014) Yuko Tashiro et al.   PEPTIDES

Advances in Pharmacologic Therapies for Type 2 Diabetes

(2013) Linde M. Morsink et al.   Current Atherosclerosis Reports

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

(2013) P.-H. Groop et al.   DIABETES CARE

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

(2013) Marcel H. A. Muskiet et al.   Nature Reviews Nephrology

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

(2012)   AMERICAN JOURNAL OF KIDNEY DISEASES

Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions

(2012) Toshimasa Shigeta et al.   CIRCULATION

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

(2012) M. Pendergrass et al.   DIABETES OBESITY & METABOLISM

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety

(2012) D. Nathanson et al.   DIABETOLOGIA

Direct effect of GLP-1 infusion on endogenous glucose production in humans

(2012) M. Seghieri et al.   DIABETOLOGIA

Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects

(2012) Jutta Keller et al.   REGULATORY PEPTIDES

A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans

(2011) Philip A. Read et al.   Circulation-Cardiovascular Interventions

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes

(2011) A. Ceriello et al.   DIABETES CARE

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

(2011) Jacob Lønborg et al.   EUROPEAN HEART JOURNAL

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

(2011) Chinmay S. Marathe et al.   Experimental Diabetes Research

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents

(2011) B. B. Dokken et al.   HORMONE AND METABOLIC RESEARCH

Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study

(2011) Magnus T Jensen et al.   European Journal of Preventive Cardiology

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

(2010) Que Liu et al.   Cardiovascular Diabetology

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons

(2010) Kathleen J. Griffioen et al.   CARDIOVASCULAR RESEARCH

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Exenatide-Associated Ischemic Renal Failure

(2009) W. J. Weise et al.   DIABETES CARE

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

(2009) P. C. Butler et al.   DIABETOLOGIA

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

(2009) J. S. Nachnani et al.   DIABETOLOGIA

Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury

(2009) Leo Timmers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study

(2008) P. M. HELLSTRÖM et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use

(2008) D. P. Kao et al.   DIABETIC MEDICINE